Physician profile
Roberto P Ramirez
NPI 1215042528
$11,047.80
in general payments reported to CMS, 2019-2025
46 companies · $1,690 in 2025
The $1,690 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $839 · 2021: $3,732 · 2022: $1,378 · 2023: $1,140 · 2024: $1,862 · 2025: $1,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,941 · Gift: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,941.35 |
| Gift | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $3,680.00 | 2021 | |
| Sekisui Diagnostics LLC | $1,195.00 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $891.76 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $839.02 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $609.77 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $504.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $422.24 | 2019-2025 | Evenity, Repatha, Otezla |
| Chugai Pharmaceutical Co., LTD. | $400.00 | 2022 | |
| Pfizer INC. | $349.82 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $288.68 | 2023-2025 | Spravato, Xarelto |
| Phathom Pharmaceuticals, INC. | $188.47 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $181.94 | 2023-2025 | Auvelity |
| Abbvie INC. | $177.27 | 2020-2024 | |
| Exact Sciences Corporation | $125.97 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $123.18 | 2019-2025 | Verquvo, Vaxneuvance, M-M-R II |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.